{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T04:01:17Z","timestamp":1778904077956,"version":"3.51.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2015,3,1]],"date-time":"2015-03-01T00:00:00Z","timestamp":1425168000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2015,3]]},"DOI":"10.1007\/s40266-015-0250-4","type":"journal-article","created":{"date-parts":[[2015,3,2]],"date-time":"2015-03-02T14:07:04Z","timestamp":1425305224000},"page":"251-260","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Brinzolamide\/Brimonidine: A Review of Its Use in Patients with Open-Angle Glaucoma or Ocular Hypertension"],"prefix":"10.1007","volume":"32","author":[{"given":"Sarah L.","family":"Greig","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emma D.","family":"Deeks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,3]]},"reference":[{"issue":"4","key":"250_CR1","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1111\/j.1442-9071.2012.02773.x","volume":"40","author":"RJ Casson","year":"2012","unstructured":"Casson RJ, Chidlow G, Wood JP, et al. Definition of glaucoma: clinical and experimental concepts. Clin Exp Ophthalmol. 2012;40(4):341\u20139.","journal-title":"Clin Exp Ophthalmol"},{"issue":"18","key":"250_CR2","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1001\/jama.2014.3192","volume":"311","author":"RN Weinreb","year":"2014","unstructured":"Weinreb RN, Aung T, Medeiros FA. The pathophysiology and treatment of glaucoma: a review. JAMA. 2014;311(18):1901\u201311.","journal-title":"JAMA."},{"key":"250_CR3","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2147\/PPA.S53162","volume":"8","author":"QH Nguyen","year":"2014","unstructured":"Nguyen QH. Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focus. Patient Prefer Adherence. 2014;8:853\u201364.","journal-title":"Patient Prefer Adherence"},{"key":"250_CR4","unstructured":"European Glaucoma Society. Terminology and guidelines for glaucoma (4th edition). 2014. http:\/\/www.eugs.org . Accessed 13 Feb 2015."},{"issue":"6","key":"250_CR5","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1001\/archopht.120.6.701","volume":"120","author":"MA Kass","year":"2002","unstructured":"Kass MA, Heuer DK, Higginbotham EJ, et al. The Ocular Hypertension Treatment Study: a randomized trial determines that topical ocular hypotensive medication delays or prevents the onset of primary open-angle glaucoma. Arch Ophthalmol. 2002;120(6):701\u201313.","journal-title":"Arch Ophthalmol."},{"issue":"11","key":"250_CR6","doi-asserted-by":"crossref","first-page":"2081","DOI":"10.1016\/j.ophtha.2014.05.013","volume":"121","author":"YC Tham","year":"2014","unstructured":"Tham YC, Li X, Wong TY, et al. Global prevalence of glaucoma and projections of glaucoma burden through 2040: a systematic review and meta-analysis. Ophthalmology. 2014;121(11):2081\u201390.","journal-title":"Ophthalmology."},{"key":"250_CR7","unstructured":"American Academy of Ophthalmology Glaucoma Panel. Preferred Practice Pattern\u00ae guidelines. Primary open-angle glaucoma. 2010. http:\/\/www.aao.org\/ppp . Accessed 13 Feb 2015."},{"key":"250_CR8","first-page":"1","volume":"4","author":"EJ Higginbotham","year":"2010","unstructured":"Higginbotham EJ. Considerations in glaucoma therapy: fixed combinations versus their component medications. Clin Ophthalmol. 2010;4:1\u20139.","journal-title":"Clin Ophthalmol."},{"key":"250_CR9","doi-asserted-by":"crossref","unstructured":"Schwartz GF, Burk C, Bennett T, et al. Adherence and persistence with glaucoma therapy: brimonidine\/timolol versus dorzolamide\/timolol and various two-bottle combinations. J Clin Exp Ophthalmol. 2012;3(8). doi: 10.4172\/2155-9570.1000248 .","DOI":"10.4172\/2155-9570.1000248"},{"issue":"2","key":"250_CR10","doi-asserted-by":"crossref","first-page":"74","DOI":"10.3109\/09286586.2011.638743","volume":"19","author":"EE Roughead","year":"2012","unstructured":"Roughead EE, Kalisch LM, Pratt NL, et al. Managing glaucoma in those with co-morbidity: not as easy as it seems. Ophthalmic Epidemiol. 2012;19(2):74\u201382.","journal-title":"Ophthalmic Epidemiol"},{"key":"250_CR11","unstructured":"Alcon Laboratories Inc. Simbrinza\u2122 (brinzolamide\/brimonidine tartrate ophthalmic suspension) 1\u00a0%\/0.2\u00a0%: US prescribing information. 2013. http:\/\/www.fda.gov . Accessed 13 Feb 2015."},{"key":"250_CR12","unstructured":"Alcon Laboratories (UK) Ltd. Simbrinza 10\u00a0mg\/mL\u00a0+\u00a02\u00a0mg\/mL eye drops, suspension: EU summary of product characteristics. 2014. http:\/\/www.ema.europa.eu . Accessed 13 Feb 2015."},{"issue":"Suppl 2","key":"250_CR13","doi-asserted-by":"crossref","first-page":"S119","DOI":"10.1016\/S0039-6257(99)00108-3","volume":"44","author":"L DeSantis","year":"2000","unstructured":"DeSantis L. Preclinical overview of brinzolamide. Surv Ophthalmol. 2000;44(Suppl 2):S119\u201329.","journal-title":"Surv Ophthalmol."},{"issue":"12","key":"250_CR14","doi-asserted-by":"crossref","first-page":"919","DOI":"10.2165\/00002512-200320120-00008","volume":"20","author":"R Cvetkovic","year":"2003","unstructured":"Cvetkovic R, Perry C. Brinzolamide. Drugs Aging. 2003;20(12):919\u201347.","journal-title":"Drugs Aging"},{"issue":"3","key":"250_CR15","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2147\/OPTH.S3182","volume":"2","author":"M Iester","year":"2008","unstructured":"Iester M. Brinzolamide ophthalmic suspension: a review of its pharmacology and use in the treatment of open angle glaucoma and ocular hypertension. Clin Ophthalmol. 2008;2(3):517\u201323.","journal-title":"Clin Ophthalmol."},{"issue":"3","key":"250_CR16","doi-asserted-by":"crossref","first-page":"225","DOI":"10.2165\/00002512-199812030-00005","volume":"12","author":"J Adkins","year":"1998","unstructured":"Adkins J, Balfour J. Brimonidine. Drugs Aging. 1998;12(3):225\u201341.","journal-title":"Drugs Aging."},{"issue":"4","key":"250_CR17","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/tcrm.2006.2.4.337","volume":"2","author":"LB Cantor","year":"2006","unstructured":"Cantor LB. Brimonidine in the treatment of glaucoma and ocular hypertension. Ther Clin Risk Manag. 2006;2(4):337\u201346.","journal-title":"Ther Clin Risk Manag."},{"issue":"3","key":"250_CR18","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/S0002-9394(99)00179-8","volume":"128","author":"CJ Ingram","year":"1999","unstructured":"Ingram CJ, Brubaker RF. Effect of brinzolamide and dorzolamide on aqueous humor flow in human eyes. Am J Ophthalmol. 1999;128(3):292\u20136.","journal-title":"Am J Ophthalmol."},{"issue":"2","key":"250_CR19","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1586\/eop.12.13","volume":"7","author":"GC Shih","year":"2012","unstructured":"Shih GC, Calkins DJ. Secondary neuroprotective effects of hypotensive drugs and potential mechanisms of action. Expert Rev Ophthamol. 2012;7(2):161\u201375.","journal-title":"Expert Rev Ophthamol."},{"issue":"12","key":"250_CR20","doi-asserted-by":"crossref","first-page":"1514","DOI":"10.1001\/archopht.1995.01100120044006","volume":"113","author":"CB Toris","year":"1995","unstructured":"Toris CB, Gleason ML, Camras CB, et al. Effects of brimonidine on aqueous humor dynamics in human eyes. Arch Ophthalmol. 1995;113(12):1514\u20137.","journal-title":"Arch Ophthalmol."},{"issue":"1","key":"250_CR21","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/S0002-9394(99)00076-8","volume":"128","author":"CB Toris","year":"1999","unstructured":"Toris CB, Camras CB, Yablonski ME. Acute versus chronic effects of brimonidine on aqueous humor dynamics in ocular hypertensive patients. Am J Ophthalmol. 1999;128(1):8\u201314.","journal-title":"Am J Ophthalmol."},{"issue":"1","key":"250_CR22","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1001\/archopht.1995.01100010079024","volume":"113","author":"JR Nordlund","year":"1995","unstructured":"Nordlund JR, Pasquale LR, Robin AL, et al. The cardiovascular, pulmonary, and ocular hypotensive effects of 0.2\u00a0% brimonidine. Arch Ophthalmol. 1995;113(1):77\u201383.","journal-title":"Arch Ophthalmol."},{"issue":"1","key":"250_CR23","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0161-6420(97)30349-2","volume":"104","author":"RJ Derick","year":"1997","unstructured":"Derick RJ, Robin AL, Walters TR, et al. Brimonidine tartrate: a one-month dose response study. Ophthalmology. 1997;104(1):131\u20136.","journal-title":"Ophthalmology."},{"key":"250_CR24","first-page":"117","volume":"3","author":"A Galanopoulos","year":"2009","unstructured":"Galanopoulos A, Goldberg I. Clinical efficacy and neuroprotective effects of brimonidine in the management of glaucoma and ocular hypertension. Clin Ophthalmol. 2009;3:117\u201322.","journal-title":"Clin Ophthalmol."},{"issue":"4","key":"250_CR25","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1001\/archophthalmol.2009.9","volume":"127","author":"M Saylor","year":"2009","unstructured":"Saylor M, McLoon LK, Harrison AR, et al. Experimental and clinical evidence for brimonidine as an optic nerve and retinal neuroprotective agent: an evidence-based review. Arch Ophthalmol. 2009;127(4):402\u20136.","journal-title":"Arch Ophthalmol."},{"key":"250_CR26","doi-asserted-by":"crossref","unstructured":"Katz GMD, DuBiner HMD, Samples JMD, et al. Three-month randomized trial of fixed-combination brinzolamide, 1\u00a0%, and brimonidine, 0.2\u00a0%. JAMA Ophthalmol. 2013;131(6):724\u201330.","DOI":"10.1001\/jamaophthalmol.2013.188"},{"issue":"3","key":"250_CR27","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1089\/jop.2012.0235","volume":"29","author":"QH Nguyen","year":"2013","unstructured":"Nguyen QH, McMenemy MG, Realini T, et al. Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1\u00a0%\/brimonidine 0.2\u00a0%. J Ocul Pharmacol Ther. 2013;29(3):290\u20137.","journal-title":"J Ocul Pharmacol Ther."},{"issue":"12","key":"250_CR28","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.ophtha.2014.06.022","volume":"121","author":"T Aung","year":"2014","unstructured":"Aung T, Laganovska G, Hernandez Paredes TJ, et al. Twice-daily brinzolamide\/brimonidine fixed combination versus brinzolamide or brimonidine in open-angle glaucoma or ocular hypertension. Ophthalmology. 2014;121(12):2348\u201355.","journal-title":"Ophthalmology."},{"issue":"12","key":"250_CR29","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s12325-014-0168-y","volume":"31","author":"SA Gandolfi","year":"2014","unstructured":"Gandolfi SA, Lim J, Sanseau AC, et al. Randomized trial of brinzolamide\/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertension. Adv Ther. 2014;31(12):1213\u201327.","journal-title":"Adv Ther."},{"key":"250_CR30","doi-asserted-by":"crossref","unstructured":"Whitson JT, Realini T, Nguyen QH, et al. Six-month results from a phase III randomized trial of fixed-combination brinzolamide 1\u00a0%\u00a0+\u00a0brimonidine 0.2\u00a0% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension. Clin Ophthalmol. 2013;7:1053\u201360.","DOI":"10.2147\/OPTH.S46881"},{"key":"250_CR31","doi-asserted-by":"crossref","unstructured":"Realini T, Nguyen QH, Katz G, et al. Fixed-combination brinzolamide 1\u00a0%\/brimonidine 0.2\u00a0% vs monotherapy with brinzolamide or brimonidine in patients with open-angle glaucoma or ocular hypertension: results of a pooled analysis of two phase 3 studies. Eye (Lond). 2013;27(7):841\u20137.","DOI":"10.1038\/eye.2013.83"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-015-0250-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-015-0250-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-015-0250-4","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:41:55Z","timestamp":1559504515000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-015-0250-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2015,3]]}},"alternative-id":["250"],"URL":"https:\/\/doi.org\/10.1007\/s40266-015-0250-4","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,3]]}}}